Changchun High-Tech (000661.SZ) subsidiary's GenSci155 injection clinical trial application accepted

Zhitong Finance APP News, Changchun High-Tech (000661.SZ) issued an announcement. Recently, the company's controlling subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical") received the "Notice of Acceptance" approved and issued by the National Medical Products Administration (NMPA). The domestic production drug registration clinical trial application for Jinsai Pharmaceutical's GenSci155 Injection has been accepted. GenSci155 Injection is a long-acting fatty acid-conjugated recombinant human insulin-like growth factor-1 (IGF-1) analog independently developed by Jinsai Pharmaceutical, with a registration classification of Class 1 therapeutic biological product. It is intended for the treatment of cerebral hemorrhage (specifically spontaneous cerebral hemorrhage), and the route of administration is intravenous injection.